Neil A. Klompas - Mar 10, 2023 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
President & COO
Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Mar 10, 2023
Transactions value $
-$23,298
Form type
4
Date filed
3/14/2023, 05:00 PM
Previous filing
Jan 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Stock Options Exercise $0 +2.5K +16.89% $0.00 17.3K Mar 10, 2023 Direct F1
transaction ZYME Common Stock Options Exercise $0 +2.71K +15.65% $0.00 20K Mar 10, 2023 Direct F2
transaction ZYME Common Stock Sale -$23.3K -2.98K -14.88% $7.83 17K Mar 10, 2023 Direct F3, F4
holding ZYME Common Stock 700 Mar 10, 2023 Held by spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Restricted Stock Unit Options Exercise $0 -2.5K -100% $0.00* 0 Mar 10, 2023 Common Stock 2.5K Direct F5, F6
transaction ZYME Restricted Stock Unit Options Exercise $0 -2.71K -49.99% $0.00 2.71K Mar 10, 2023 Common Stock 2.71K Direct F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020.
F2 Represents shares of common stock issued upon vesting of one third of the RSUs granted on March 10, 2021.
F3 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.815 to $7.86, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F6 The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021.
F7 The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022.